Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.53 |
| ▸ | CCR6 | P51684 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18677769 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL28110623 | 0.92 | HSP90AA1 (0.61) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27683564 | 0.82 | MGLL (0.51) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27758211 | 0.82 | MGLL (0.44) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27822379 | 0.81 | MAPK13 (0.55) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL26688275 | 0.79 | FAAH (0.50) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27895956 | 0.77 | MAPK1 (0.48) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27438302 | 0.77 | LMNA (0.51) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27845392 | 0.77 | LMNA (0.49) | CYP1A2ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL27361912 | 0.77 | GAA (0.37) | CYP1A2ALDH1A1MAPTNPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119931531-A | EPE type co-extrusion photovoltaic packaging adhesive film based on D-A dynamic crosslinking, preparation method and application thereof | 苏州易昇光学材料股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | claimed |
| WO-2007075911-A2 | INHIBITION OF GLYCOGEN SYNTHASE KINASE AND METHODS OF TREATING AUTOIMMUNE OR IMMUNE INFLAMMATORY DISEASE | YALE UNIVERSITY (US) | 2007-07-05 | — | — | WO | claimed |
| CN-1030353-C | Nonlinear optical materials | DU PONT (US) | 1995-11-22 | — | — | CN | claimed |
| CN-1059344-A | Nonlinear optical material | DU PONT (US) | 1992-03-11 | — | — | CN | claimed |
| CN-119931531-A | EPE type co-extrusion photovoltaic packaging adhesive film based on D-A dynamic crosslinking, preparation method and application thereof | 苏州易昇光学材料股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | INSTITUT PASTEUR (FR) | 2025-04-03 | — | — | US | disclosed |
| WO-2024086347-A1 | METHODS OF DESIGING MOLECULAR GLUE DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2023-11-07 | — | — | US | disclosed |
| US-20220288151-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2022-09-15 | — | — | US | disclosed |
| EP-4010020-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES | Carmel-Haifa University Economic Corporation Ltd. (IL) | 2022-06-15 | — | — | EP | disclosed |
| WO-2007075911-A2 | INHIBITION OF GLYCOGEN SYNTHASE KINASE AND METHODS OF TREATING AUTOIMMUNE OR IMMUNE INFLAMMATORY DISEASE | YALE UNIVERSITY (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076372-A2 | TREATMENT OF NEUROAIDS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 | UNIVERSITY OF ROCHESTER (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007016485-A2 | USE OF A GSK-3 INHIBITOR TO MAINTAIN POTENCY OF CULTURED CELLS | ATHERSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006083937-A2 | AGENTS AND METHODS RELATED TO REDUCING RESISTANCE TO APOPTOSIS-INDUCING DEATH RECEPTOR AGONISTS | THE UAB RESEARCH FOUNDATION (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-1995018801-A1 | BENZIMIDAZOLYL QUINOLINE-3-CARBOXYLATE DERIVATIVES, INTERMEDIATES THERETO, AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-07-13 | — | — | WO | disclosed |
| EP-0257433-B1 | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID CO (US) | 1994-03-23 | — | — | EP | disclosed |
| US-4757146-A | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0257433-A2 | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | GSK3B, GSK3A, GSKIP | CYP1A2 1833/4885ALDH1A1 4236/4885MAPT 1196/4885 |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | ICOS, CD4, NFATC1 | CYP1A2 4793/4885ALDH1A1 3638/4885MAPT 3028/4885 |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, POLA1, POLR2B | CYP1A2 1506/4885ALDH1A1 2997/4885MAPT 3738/4885 |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, TOP2A, POLI | CYP1A2 2083/4885ALDH1A1 3656/4885MAPT 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.